The present disclosure relates to stable formulations of receptor tyrosine kinase inhibitors (TKI) pazopanib methods of preparation thereof and use of the disclosed formulations in sustained delivery of the active agent to a target site. The disclosure further relates to methods of converting one polymorphic Form of a TKI to another polymorphic Form and/or an amorphous form.